In particular, Zipalertinib and CLN-978 stand out as its most promising product candidates. Zipalertinib targets a tiny niche in the large NSCLC market. Management expects to report its Phase 2b ...

There is no Morningstar’s Analysis data available.

For those in our community who don’t know it, there is a group working tirelessly to censor and remove books from our local libraries and schools. I am alarmed by the list of supposed ...